The US Government keeps an online database, at clinicaltrials.gov, of clinical research studies for Mesothelioma cancer, but doesn't review or approve the safety and science of these trials. The website is maintained by the National Library of Medicine (NLM). The links below go to the clinical trial information on clinicaltrials.gov. Talk with your health care professional about possible risks and benefits before joining any studies.
Fri, 21 Feb 2025 00:00:00 EST
Conditions: Pleural Mesotheliomas
Interventions: Drug: Ivonescimab
Sponsors: Intergroupe Francophone de Cancerologie Thoracique; Summit Therapeutics
Not yet recruiting
Fri, 21 Feb 2025 00:00:00 EST
Conditions: Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies
Interventions: Drug: alrizomadlin
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
Fri, 21 Feb 2025 00:00:00 EST
Conditions: Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Pancreatic Adenocarcinoma; Colorectal Neoplasms; Mesothelioma; Other Solid Tumors; Endometrial
Interventions: Drug: PF-08052666
Sponsors: Seagen Inc.
Recruiting
Wed, 12 Feb 2025 00:00:00 EST
Conditions: Advanced Solid Tumor; Mesothelioma, Malignant
Interventions: Drug: SW-682; Drug: Combination Therapy
Sponsors: SpringWorks Therapeutics, Inc.
Recruiting
Tue, 11 Feb 2025 00:00:00 EST
Conditions: Pleural Mesothelioma
Interventions: Drug: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
Sponsors: Istituto Oncologico Veneto IRCCS; MSD Italia S.r.l.
Recruiting
Tue, 18 Feb 2025 00:00:00 EST
Conditions: Unresectable Pleural Mesothelioma
Interventions: Drug: Volrustomig; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: AstraZeneca
Recruiting
Fri, 14 Feb 2025 00:00:00 EST
Conditions: Locally Advanced Solid Tumor
Interventions: Drug: TNG462; Drug: Pembrolizumab
Sponsors: Tango Therapeutics, Inc.
Recruiting
Wed, 19 Feb 2025 00:00:00 EST
Conditions: Cutaneous Melanoma; Non-small Cell Lung Cancer; Colorectal Neoplasms; Pancreatic Neoplasms; Mesothelioma
Interventions: Drug: PF-08046049
Sponsors: Seagen, a wholly owned subsidiary of Pfizer
Recruiting
Mon, 17 Feb 2025 00:00:00 EST
Conditions: Peritoneal Malignant Mesothelioma
Interventions: Biological: Atezolizumab; Biological: Bevacizumab; Procedure: Biospecimen Collection; Drug: Carboplatin; Procedure: Computed Tomography; Procedure: Cytoreductive Surgery; Drug: Hyperthermic Intraperitoneal Chemotherapy; Drug: Pemetrexed; Procedure: Positron Emission Tomography
Sponsors: National Cancer Institute (NCI)
Recruiting
Wed, 19 Feb 2025 00:00:00 EST
Conditions: All Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Diffuse Large B-Cell Lymphoma (DLBCL); Epithelioid Sarcoma (ES); Synovial Sarcoma; Renal Medullary Carcinoma; Mesothelioma; Rhabdoid Tumor
Interventions: Drug: Tazemetostat; Drug: Itraconazole; Drug: Tazemetostat; Drug: Rifampin
Sponsors: Epizyme, Inc.
Completed